A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes

Exclusion Criteria

• •1. Known or suspected allergy or intolerance to the investigational medicinal products or related products；
• •2. Acute complications of diabetes occurred during the previous 6 months；
• •3. Serious chronic complications of diabetes in the past；
• •4. Use other antidiabetic drugs for ≥3months prior to screening ;
• •5. Before screening, have disease or treatment that may affect weight; or any previous condition that may affect gastric emptying； or gastrointestinal surgery;
• •6. Participation in any clinical trial of an approved or non-approved investigational product/treatment within the last 3 months or 5 half-lives, whichever is longer, prior to screening;
• •7. Any conditions that the Investigator judges might not be suitable to participate in the trial.